The Skintel Melanin Reader from Palomar Medical Technologies (Burlington, MA) determines average melanin density in an area of skin to be treated, in a quantitative manner, prior to a light-based aesthetic treatment. The reader measures skin diffuse reflectance at three wavelengths of light and computes these values into a Melanin Index value, which wirelessly sets the suggested parameters in the company's Icon Aesthetic System for a starting treatment test spot fluence.
-----
PRESS RELEASE
Palomar Medical Technologies Introduces the Skintel Melanin Reader
Tuesday, March 13, 2012
Palomar Medical Technologies Introduces the Skintel Melanin Reader - For Increased Confidence in Administering Aesthetic Treatments
Burlington, MA., [March 13, 2012] - Palomar Medical Technologies, Inc. (NASDAQ: PMTI), a leading researcher and developer of lasers and light systems for aesthetic treatments, is pleased to announce the availability of the revolutionary Skintel™ Melanin Reader - the only FDA-cleared melanin reader for use with light-based treatments. The Skintel reader will be introduced at the 70th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego, California, from March 16th through March 20th.
"The Skintel Melanin Reader is truly a game-changing innovation for aesthetic providers," remarked Joseph P. Caruso, President and Chief Executive Officer. "The Skintel reader was developed by Palomar's outstanding research organization to better and more accurately measure skin melanin density."
The Skintel reader provides an additional element of treatment confidence by determining an average melanin density in an area of skin to be treated, in a quantitative manner, prior to a light-based aesthetic treatment - such as hair removal or photorejuvenation. Understanding how much melanin is in the skin helps the aesthetic professional to better choose the treatment settings on the Palomar Icon Aesthetic System for enhanced treatment outcomes, while minimizing risk of over treatment.
E. Victor Ross, M.D., Director of the Scripps Clinic Laser and Cosmetic Dermatology Center in Carmel Valley, CA, participated in the clinical validation of the Skintel reader. "The Skintel Melanin Reader is a better, more advanced way to look at skin typing compared to the conventional Fitzpatrick method," said Dr. Ross. "The Skintel reader helps keep my eyeball honest. You can't always accurately evaluate skin visually, especially in areas where there is underlying redness overlaid with pigmentation. The Skintel reader helps me understand what's truly going on under the skin."
Jeremy Green, M.D., a board-certified dermatologist in private practice in Coral Gables, FL, feels that the Skintel Melanin Reader helps him better serve his patients' needs. "The objectivity of the Skintel reader takes the guess work out of assessing a patient's skin. It provides me with added confidence in treating my patients successfully from the first treatment."
The Skintel Melanin Reader measures skin diffuse reflectance at three unique wavelengths of light and computes these values into a Melanin Index value, which wirelessly sets the suggested parameters in the Palomar Icon Aesthetic System for a starting treatment test spot fluence. The Skintel reader offers practitioners a quantitative method of measuring melanin content for better treatment guidance and for increased confidence in aesthetic light-based treatments.
To learn more about the Skintel Melanin Reader and the Palomar Icon Aesthetic System, please visit palomarmedical.com. Attendees at the AAD Annual Meeting can experience Skintel first-hand at Booth #1227.
About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of laser- and light-based systems for aesthetic treatments.
Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription.
As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, fractional laser device for the treatment of periorbital wrinkles. Palomar introduced the PaloVia™ Skin Renewing Laser™ in December 2010. In December 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment.
There are now millions of laser- and light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas, salons, and homes. Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.
For more information on Palomar and its products, visit Palomar's website at palomarmedical.com.
-----
Follow us on Twitter
Subscribe now to Laser Focus World magazine; it's free!